IMPACT-HTN Study of Patients With Hypertension

An estimated 120 million people have high blood pressure (hypertension) in the US, of which approximately 10% have resistant hypertension. This study aims to enroll patients who continue to have hypertension while being treated with at least two medications. The study will follow patients for approximately 3 months and collect real-world information on changes in their health to identify an ideal patient profile that would benefit from 4th-line antihypertensive therapies, including, but not limited to, FDA-approved aprocitentan, renal denervation, mineralocorticoid receptor antagonists, etc.

Inclusion Criteria: * Signed and dated informed consent form * Ability to answer survey questions and to report blood pressure reading monthly * Male and female participants; 18 years or older * Treated with at least 2 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit * Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 130 mmHg Exclusion Criteria: * Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and/or Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg * Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator * Heart failure NYHA functional class III and IV or NT-proBNP \> 500 pg/mL * Severe renal insufficiency or eGFR \< 15 mL/min/1.73m2 * Moderate to severe hepatic impairment (Child-Pugh B and C) or elevated aminotransferase (\> 3 x ULN)